- In February 2025, RegeneraSight Biologics announced the initiation of Phase III trials for its next-generation recombinant human nerve growth factor (rhNGF) eye drop, optimized for faster epithelial healing in neurotrophic keratitis patients across North America and Europe
- In October 2024, BioTissue Inc. reported positive Phase II trial outcomes for its cryopreserved amniotic membrane therapy, demonstrating enhanced corneal healing in patients with persistent epithelial defects in both U.S. and European cohorts
